Sucampo Pharmaceuticals, Inc. (SCMP) Scheduled to Post Quarterly Earnings on Tuesday
Sucampo Pharmaceuticals, Inc. (NASDAQ:SCMP) is set to issue its quarterly earnings data before the market opens on Tuesday, November 7th. Analysts expect the company to announce earnings of $0.26 per share for the quarter.
Sucampo Pharmaceuticals (NASDAQ:SCMP) last released its earnings results on Wednesday, August 2nd. The biopharmaceutical company reported $0.28 EPS for the quarter, topping the Zacks’ consensus estimate of $0.22 by $0.06. Sucampo Pharmaceuticals had a positive return on equity of 56.58% and a negative net margin of 61.99%. The firm had revenue of $59.90 million during the quarter, compared to the consensus estimate of $56.44 million. During the same quarter in the previous year, the company posted $0.24 earnings per share. The company’s revenue was up 15.3% compared to the same quarter last year. On average, analysts expect Sucampo Pharmaceuticals to post $1.010 EPS for the current fiscal year and $1.040 EPS for the next fiscal year.
Shares of Sucampo Pharmaceuticals, Inc. (NASDAQ:SCMP) opened at 9.50 on Tuesday. The firm’s market cap is $440.09 million. The company’s 50 day moving average price is $11.04 and its 200-day moving average price is $10.68. Sucampo Pharmaceuticals, Inc. has a 12-month low of $9.30 and a 12-month high of $17.55.
SCMP has been the topic of a number of research reports. Zacks Investment Research upgraded Sucampo Pharmaceuticals from a “hold” rating to a “buy” rating and set a $11.00 price target on the stock in a research note on Tuesday, October 17th. UBS AG dropped their price target on Sucampo Pharmaceuticals from $19.00 to $15.00 and set a “buy” rating on the stock in a research note on Thursday, October 12th. Leerink Swann initiated coverage on Sucampo Pharmaceuticals in a research note on Monday, August 21st. They set an “outperform” rating and a $15.00 price target on the stock. Roth Capital set a $30.00 price target on Sucampo Pharmaceuticals and gave the stock a “buy” rating in a research note on Thursday, August 3rd. Finally, Maxim Group restated a “buy” rating and set a $23.00 price target (up previously from $21.00) on shares of Sucampo Pharmaceuticals in a research note on Tuesday, August 8th. Three research analysts have rated the stock with a hold rating and seven have assigned a buy rating to the stock. The company presently has a consensus rating of “Buy” and an average price target of $16.50.
TRADEMARK VIOLATION NOTICE: “Sucampo Pharmaceuticals, Inc. (SCMP) Scheduled to Post Quarterly Earnings on Tuesday” was published by American Banking News and is the sole property of of American Banking News. If you are viewing this article on another website, it was stolen and republished in violation of U.S. & international copyright and trademark legislation. The legal version of this article can be accessed at https://www.americanbankingnews.com/2017/10/31/sucampo-pharmaceuticals-inc-scmp-scheduled-to-post-quarterly-earnings-on-tuesday.html.
In related news, insider Jason Patrick Meyenburg bought 4,000 shares of the stock in a transaction on Wednesday, September 6th. The shares were bought at an average cost of $12.13 per share, for a total transaction of $48,520.00. Following the purchase, the insider now owns 30,228 shares of the company’s stock, valued at approximately $366,665.64. The acquisition was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, insider Jones W. Bryan bought 4,700 shares of the stock in a transaction on Friday, August 4th. The stock was bought at an average price of $10.60 per share, for a total transaction of $49,820.00. Following the completion of the purchase, the insider now directly owns 4,700 shares in the company, valued at approximately $49,820. The disclosure for this purchase can be found here. Company insiders own 4.13% of the company’s stock.
Sucampo Pharmaceuticals Company Profile
Sucampo Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of pharmaceutical products. Its primary focus areas are gastroenterology, ophthalmology and oncology-related disorders. Its product candidates include VTS-270, Lubiprostone (AMITIZA), Unoprostone is opropyl (RESCULA) and CPP-1X/sulindac combination product.
Receive News & Ratings for Sucampo Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sucampo Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.